This article delves into the analysis of the impact of bio-realization engineering technologies on cancer diagnostic processes within the contemporary healthcare system. The objective of the article is to identify the potential of molecular-genetic testing and other bio-realization methods in enhancing diagnostic capabilities and therapeutic approaches for oncological diseases. To achieve this goal, general scientific methods of analysis and synthesis of existing research in this field are utilized, including a review of scientific literature and a critical analysis of the results of experimental studies. The findings confirm the significant impact of bio-realization engineering technologies on the advancement of cancer diagnostics. Specifically, molecular-genetic testing opens new avenues for early detection and personalized treatment approaches for cancer, based on the genetic characteristics of tumors. These technologies are particularly valuable for countries with limited medical resources, as they offer cost-effective and efficient solutions that provide broader access to quality diagnostic services. They also contribute to improving the overall efficacy of treatment strategies and optimizing medical research, reducing the burden on medical staff. The practical significance of the obtained results lies in the possibility of their application in the development of new diagnostic tools and techniques aimed at enhancing the accuracy, accessibility, and efficiency of cancer treatment. This, in turn, may contribute to reducing mortality from oncological diseases and improving patients' quality of life. Bio-realization engineering technologies, particularly molecular-genetic testing, play a pivotal role in modern oncological diagnostics, offering promising opportunities for the improvement of diagnostic and therapeutic procedures for cancer. Their integration into the healthcare system enhances diagnostic accuracy, treatment accessibility, and the overall level of medical services, opening new horizons in the fight against oncological diseases.